We found that CD133 increased with the emergence of drug-resistance phenotypes, and targeting CD133 reversed drug resistance via the AKT/NF-κB/MDR1 pathway, further providing a potential therapeutic target to reverse MDR in CRC. This evidence concerns the gene AKT1 and colorectal carcinoma.